We are working on 1st line and Pancreatic. Intuitively, we believe as you do that the numbers may be supportive of PPHM effort overall.
Both clinicals are long enrollment periods and non- linear ramp up. If I ever get comfortable with the estimates I will revert back. I have long felt that the "measurement" used in the 1st line NSCLC was flawed and aberrant and that the overall result would revert more to the mean which would be more favorable to PPHM.